Conroy Gold and Natural Resources (CGNR) announced it has discovered antimony-bearing float samples from its Clontibret gold deposit area in County Monaghan, Ireland. The samples returned very high gold grades of 21.9 g/t Au and 11.2 g/t Au and results for antimony were above detection limits greater than 1% (10,000 ppb).
The samples are with ALS Laboratory for detailed assaying in relation to antimony ore grade content in the samples. Encouraging preliminary analysis has already been obtained onsite using a portable X-ray Fluorescence (pXRF) instrument, which returned indicative results in excess of 40 per cent. antimony.
Comment: Apart from a brief spike in February, shares of CGNR have not taken part in the great 2025 bull run for gold. Therefore it may be that the latest news regarding newly hot antimony is a timely boost.
Rightmove (RMV), the UK’s number one property portal, updated on trading for the period from 1 January 2025. Figures relate to the four-month period ending 30 April 2025. Guidance remains unchanged since our 2024 full-year results, and we are reiterating our expectation of 8-10% revenue growth in 2025. In the Resale market, house price growth remains positive with year-on-year increases in new buyer demand (+5%), new property listings (+9%) and sales agreed (+7%).
Comment: RMV is in the happy position of being the provider of the picks and shovels for the gold rush, even as the UK property market is battered by stamp duty and affordability issues. But at least yesterday’s interest rate cut arrives just in time to help the sector.
Oxford BioDynamics (OBD), a precision clinical diagnostics company confirmed the successful completed validation of its EpiSwitch Checkpoint Inhibitor Response Test (CiRT) as a clinical test in this UK laboratory. CiRT is OBD’s best-in-class stratification tool that empowers clinicians to identify which patients are likely to respond to a widely used class of immunotherapies: immune checkpoint inhibitors. The CiRT blood test is already available in the UK, but up to now, testing was performed in OBD’s US CLIA-certified facility.
Comment: Having delivered a big fundraise at the start of this year, it is key for the company to deliver the kind of significant newsflow to appease those who bought into the company. Best in class diagnostics, and partnerships with key players such as Bupa start the fightback, as the company chases revenue.
Brave Bison (BBSN), the digital media, marketing and technology company, notes recent press speculation and confirms that it has entered into exclusive negotiations to acquire MiniMBA from Centaur Media plc for an enterprise value of £19 million.
Comment: One might have thought that humble old BBSN was too small to be scooped by Sky News, but luckily for fans of the small cap space, it made the grade. The company continues to be one of the few on the London market which seems to be a genuine buy and build situation.
Belluscura (BELL), a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies, provides the following trading update and announces the commencement of a strategic review. The Company confirms that, subject to any future regulatory changes, the US import tariff on its portable oxygen containers remains at zero. This continues to support Belluscura’s cost structure and reinforces its ability to offer competitively priced products.
Comment: Given that the company was not able to finesse the once in a lifetime opportunity of COVID, it is perhaps a relief that it will not be affected by the tariffs, which given the current share price and sentiment, would have added insult to injury.
Genflow Biosciences (GENF) announced that it has raised gross proceeds of £500,000 at an issue price of 0.8 pence. The net proceeds of this fundraise will be used to advance a proof-of-concept trial evaluating the safety and efficacy of our therapeutic candidate in aged dogs, potentially being also a key translational model for age-related conditions in humans.
Comment: Given that GENF has been a regular recipient of grant funding, one might have thought that an additional fundraise was not required. Nevertheless, the stakes are high given that we all need that proverbial fountain of youth.
Tiger Royalties and Investments (TIG), an investment vehicle focused on incubating technology and mining projects, announced its strategic entry into the fast-emerging decentralised AI space via Tao Strategies Singapore. As a cornerstone investor, Tiger has signed a Letter of Intent to invest £250,000 in Tao Strategies, a dedicated operator of miner and validator nodes and subnodes on the Bittensor network.
Comment: While it may be the case that most London investors over the age of 50 are not fully au fait with AI, let alone its decentralized version, yesterday’s share price rise for TIR ahead of today’s news shows that the newly rebooted company is in favour with the cognoscenti.
Physiomics (PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions announced a contract award with a new UK client. The project will involve the application of population Pharmacokinetic (PK) modelling techniques using Phase 1 data to inform the Phase 2 study of a small molecule designed to treat rheumatoid arthritis. The project, valued at £67,500.
Comment: The £67,500 contract may not have PYC knocking on the door of the FTSE 100 just yet, but it does appear there is some interest in the stock near recent support levels.
Disclaimer & Declaration of Interest:
The information, investment views, and recommendations in this Zaks Traders Cafe interview are provided for general information purposes only. Nothing in this interview should be construed as a promotion or solicitation to buy or sell any financial product relating to any companies under discussion or referred to or to engage in or refrain from doing so or engage in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion.
